Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + TQB2450 in Advanced ESCC
NCT05038813Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart and anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
benmelstobartanlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05038813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038813.